Leqembi wins NMPA nod for once-monthly IV dosing in early Alzheimer’s patients

LEQEMBI was initially approved in China in January 2024 for the treatment of Alzheimer’s disease in patients with mild cognitive impairment

GSK names Luke Miels as next CEO

Miels will formally assume the role on January 1, 2026

BMS launches BMS patient connect, expands direct-to-patient access with Sotyktu

Eliquis (apixaban) available at more than 40 per cent discount; Sotyktu to be offered at more than 80 per cent discount to current list price

FDA authorizes first eyeglass lenses to slow progression of pediatric Myopia

FDA authorization was based on two years of clinical study data demonstrating that Essilor Stellest lenses significantly slowed myopia progression compared to single-vision control lenses

Enhertu improved in invasive disease-free survival in early breast cancer in DB-05

Second positive Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu in HER2-positive early breast cancer reinforces its potential to become a foundational treatment option in curative-intent setting

Experts highlight critical link between mental well-being and cardiovascular health

Health leaders rally for a national awakening on prevention, mental wellness, and lifestyle reform at ‘Illness to Wellness’ heart care conference

Sanofi boosts Sanofi Ventures with additional $625 million September 24, 2025

Sanofi Ventures drives innovation through leading and participating in private financing rounds for pioneering healthcare companies

Amgen invests $650 million on expansion of US manufacturing network

Amgen has invested over $40 billion in manufacturing and research and development in US since 2017

AstraZeneca to harmonise its listing structure across LSE, STO and NYSE

Harmonisation of listing structure requires a direct listing of AstraZeneca shares on the NYSE in place of existing US ADRs

Cayman, Akadeum to revolutionize cell isolation for cell and gene therapy